<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006149.pub2" GROUP_ID="HIV" ID="621105121913114026" MERGED_FROM="" MODIFIED="2011-09-06 01:11:55 +0200" MODIFIED_BY="Tara Horvath" NOTES="&lt;p&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.8&lt;/p&gt;&lt;p&gt;Old title: Interventions for treating AIDS-associated Hodgkin&amp;#180;s Lymphoma in treatment-naive adults with AIDS&lt;/p&gt;" NOTES_MODIFIED="2011-09-05 16:02:05 -0700" NOTES_MODIFIED_BY="Tara Horvath" REVIEW_NO="AM02" REVMAN_SUB_VERSION="5.1.0" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2011-09-06 01:11:55 +0200" MODIFIED_BY="Tara Horvath">
<TITLE>Interventions for treating AIDS-associated Hodgkin´s lymphoma in treatment-naive adults</TITLE>
<CONTACT MODIFIED="2011-09-06 01:11:55 +0200" MODIFIED_BY="Tara Horvath"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Universidad de Carabobo and Iberoamerican Cochrane Network</ORGANISATION><CITY>Valencia</CITY><REGION>Edo. Carabobo</REGION><COUNTRY CODE="VE">Venezuela</COUNTRY><PHONE_1>+58 241 8712883</PHONE_1><FAX_1>+58 241 8712883</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-09-06 01:11:55 +0200" MODIFIED_BY="Tara Horvath"><PERSON ID="0B71502082E26AA2005EBC6E010990A2" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Arturo</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>Martí-Carvajal</LAST_NAME><SUFFIX>MD, MSc</SUFFIX><EMAIL_1>arturo.marti.carvajal@gmail.com</EMAIL_1><ADDRESS><ORGANISATION>Universidad de Carabobo and Iberoamerican Cochrane Network</ORGANISATION><CITY>Valencia</CITY><REGION>Edo. Carabobo</REGION><COUNTRY CODE="VE">Venezuela</COUNTRY><PHONE_1>+58 241 8712883</PHONE_1><FAX_1>+58 241 8712883</FAX_1></ADDRESS></PERSON><PERSON ID="14497" ROLE="AUTHOR"><FIRST_NAME>Andrés Felipe</FIRST_NAME><LAST_NAME>Cardona</LAST_NAME><SUFFIX>MD, MSc, PhDc</SUFFIX><POSITION>Clinical Oncologist</POSITION><EMAIL_1>a_cardonaz@yahoo.com</EMAIL_1><EMAIL_2>acardonaz@yahoo.com</EMAIL_2><ADDRESS><DEPARTMENT>Clinical and Translational Oncology Group</DEPARTMENT><ORGANISATION>Institute of Oncology, Fundación Santa Fe de Bogotá</ORGANISATION><ADDRESS_1>Calle 119 No. 7 - 75</ADDRESS_1><CITY>Bogotá</CITY><ZIP>0571</ZIP><REGION>Cundinamarca</REGION><COUNTRY CODE=" CO">Colombia</COUNTRY><PHONE_1>+571 6030303 (5227)</PHONE_1></ADDRESS></PERSON><PERSON ID="DC83D74F82E26AA201BA4B547566A9C9" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Myriam Lucía</FIRST_NAME><LAST_NAME>Rodríguez</LAST_NAME><POSITION>Internal Medicine and Hematology</POSITION><EMAIL_1>consensoshem@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Hematology and Bone Marrow Transplantation Department</DEPARTMENT><ORGANISATION>National Cancer Institute of Colombia</ORGANISATION><ADDRESS_1>Calle 1a No. 9-85, piso 4</ADDRESS_1><CITY>Bogota</CITY><COUNTRY CODE=" CO">Colombia</COUNTRY><PHONE_1>571 3341111</PHONE_1><FAX_1>+571 3341260</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-10 17:01:59 -0800" MODIFIED_BY="Tara Horvath" NOTES="&lt;p&gt;Minor update: 31/01/07&lt;/p&gt;" NOTES_MODIFIED="2008-11-10 17:01:59 -0800" NOTES_MODIFIED_BY="Tara Horvath">
<UP_TO_DATE>
<DATE DAY="19" MONTH="2" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="19" MONTH="2" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="12" YEAR="2008"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2007"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2007"/>
</DATES>
<WHATS_NEW MODIFIED="2011-09-05 16:02:05 -0700" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-09-05 16:02:05 -0700" MODIFIED_BY="Tara Horvath">
<DATE DAY="5" MONTH="9" YEAR="2011"/>
<DESCRIPTION>
<P>Minor amendment to title of plain language summary</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-09-05 16:01:41 -0700" MODIFIED_BY="Tara Horvath">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-09-05 16:01:41 -0700" MODIFIED_BY="Tara Horvath">
<DATE DAY="29" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="19" MONTH="2" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Universidad de Carabobo</NAME>
<COUNTRY CODE="VE">Venezuela</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Iberoamerican Cochrane Center</NAME>
<COUNTRY CODE="ES">Spain</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-09-05 16:01:27 -0700" MODIFIED_BY="Tara Horvath">
<SUMMARY MODIFIED="2011-09-05 16:01:27 -0700" MODIFIED_BY="Tara Horvath">
<TITLE MODIFIED="2011-09-05 16:01:27 -0700" MODIFIED_BY="Tara Horvath">Interventions for previously untreated AIDS-associated Hodgkin´s lymphoma in adults</TITLE>
<SUMMARY_BODY MODIFIED="2011-09-05 16:00:54 -0700" MODIFIED_BY="Tara Horvath">
<P>There is a lack of evidence from randomised controlled trials for the efficacy and safety of different interventions for treating AIDS-associated Hodgkin's disease, regarding both overall survival and disease-free survival in treatment-naive adults with AIDS. Lymphoma is a cancer of the lymphatic system. Lymphomas are classified into two general types: Hodgkin's disease and non-Hodgkin's lymphomas. Hodgkin's disease is the most common non-AIDS-defining malignancy in HIV-infected patients. Randomised controlled trials for the efficacy and safety of different interventions for treating AIDS-associated Hodgkin's disease on overall survival and disease-free survival in treatment-naive adults with AIDS could not be found.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-04-22 06:32:53 -0700" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Hodgkin's disease (HD) is the most common non-AIDS-defining malignancy in HIV-infected patients. Its unusually aggressive tumour behaviour includes a higher frequency of unfavourable histologic subtypes, high-stage and extranodal involvement by the time of presentation (anal canal, stomach), and poor therapeutic outcome, in comparison with HD outside the HIV setting. The optimal therapeutic strategy is still controversial, and median overall survival is short, ranging from 12 to 18 months. Thus, there is a need to identify the efficacy and safety of different interventions for AIDS-associated HD on overall survival and disease-free survival in treatment-naive adults with AIDS.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-04-22 06:32:53 -0700" MODIFIED_BY="[Empty name]">
<P>To assess the effects of different interventions for treating AIDS-associated Hodgkin's disease including chemotherapy, bone marrow transplantation (BMT), and gene therapy on overall survival and disease-free survival in treatment-naive adults with AIDS.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched The Cochrane HIV/AIDS Group Trials Register (September 2006), which comprises references identified from comprehensive electronic database searches and handsearching of relevant journals and abstract books of conference proceedings. We also searched the Cochrane Central Register of Controlled Trials<I> </I>(CENTRAL) in <I>The Cochrane Library</I> (Issue 3, 2006), MEDLINE (1966 to September 2006), EMBASE (1974 to September 2006) LILACS (1982 to September 2006), ISI Web of Knowledge (1993 to September 2006), and AIDSearch (1980 to December 2006). </P>
<P>Date of most recent search: December 2006.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We searched for published or unpublished randomised controlled trials.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>We intended to summarise data by standard Cochrane Collaboration methodologies, but no eligible randomised controlled trials were identified.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>We were unable to find any randomised controlled trials of interventions for treating AIDS-associated HD in treatment-naive adults with AIDS.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Randomised controlled trials are needed to establish the efficacy and safety of interventions for treating AIDS-associated HD in treatment-naive adults with AIDS.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-04-22 06:33:46 -0700" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-04-22 06:33:04 -0700" MODIFIED_BY="[Empty name]">
<P>Lymphoma is a haemopoietic malignancy. Lymphomas are divided into two general types: Hodgkin's disease (HD) and non-Hodgkin's (NHL) using the 2001 World Health Organization classification (<LINK REF="REF-Ellis-2005" TYPE="REFERENCE">Ellis 2005</LINK>; <LINK REF="REF-Lu-2005" TYPE="REFERENCE">Lu 2005</LINK>). Infection with human immunodeficiency virus (HIV), the virus that leads to acquired immunodeficiency syndrome (AIDS), is known to be associated with an increased risk of both types of lymphoma (<LINK REF="REF-Lyter-1995" TYPE="REFERENCE">Lyter 1995</LINK>; <LINK REF="REF-Serraino-2000" TYPE="REFERENCE">Serraino 2000</LINK>; <LINK REF="REF-Wood-2005" TYPE="REFERENCE">Wood 2005</LINK>). HD is the most common non-AIDS-defining malignancy in HIV-infected patients (<LINK REF="REF-Besson-2003" TYPE="REFERENCE">Besson 2003</LINK>; <LINK REF="REF-Hoffmann-2004" TYPE="REFERENCE">Hoffmann 2004</LINK>). Its unusually aggressive tumour behaviour includes a higher frequency of unfavourable histologic subtypes, high-stage and extranodal involvement by the time of presentation (anal canal, stomach), and poor therapeutic outcome in comparison with HD outside the HIV setting (<LINK REF="REF-Ponzoni-2002" TYPE="REFERENCE">Ponzoni 2002</LINK>; <LINK REF="REF-Massarweh-2003" TYPE="REFERENCE">Massarweh 2003</LINK>; <LINK REF="REF-Parekh-2003" TYPE="REFERENCE">Parekh 2003</LINK>; <LINK REF="REF-Doweiko-2004" TYPE="REFERENCE">Doweiko 2004</LINK>; <LINK REF="STD-Hartmann-2004" TYPE="STUDY">Hartmann 2004</LINK>; <LINK REF="REF-Thompson-2004" TYPE="REFERENCE">Thompson 2004</LINK>; <LINK REF="REF-Hilman-2005" TYPE="REFERENCE">Hilman 2005</LINK>). The course, presentation, and outcome of HD are markedly altered in HIV-infected patients (<LINK REF="REF-Poluri-2002" TYPE="REFERENCE">Poluri 2002</LINK>). It is an aggressive disease with demographic, clinical, and prognostic features nearly identical to those of HIV-related NHL (<LINK REF="REF-Re-2001" TYPE="REFERENCE">Re 2001</LINK>). Unlike HD in the general population, the large majority of HIV-related HD cases are pathogenically linked to Epstein-Barr virus (EBV), with rates of EBV positivity ranging from 80 to 100% (<LINK REF="REF-Dolcetti-2001" TYPE="REFERENCE">Dolcetti 2001</LINK>).</P>
<P>The relative incidence of HD is approximately seven times higher in HIV-infected patients than in those without HIV infection (<LINK REF="REF-Rapezzi-2001" TYPE="REFERENCE">Rapezzi 2001</LINK>). In the USA, the annual HD incidence rate has been calculated in 36.2 per 100,000 person-years (<LINK REF="REF-Biggar-2006" TYPE="REFERENCE">Biggar 2006</LINK>); while in Germany, it is 19 (95% CI 12 to 28) per 100,000 patient-years (<LINK REF="REF-Mosthaf-2006" TYPE="REFERENCE">Mosthaf 2006</LINK>). With the extension of the survival expectancy of HIV patients, HD has been recently reported with increased frequency in patients with HIV infection (<LINK REF="REF-Berretta-2003" TYPE="REFERENCE">Berretta 2003</LINK>). For example, the incidence of HD was higher in a cohort of HIV-infected patients than in the French general population (<LINK REF="REF-Herida-2003" TYPE="REFERENCE">Herida 2003</LINK>). However, one study suggests that HD has a low incidence in HIV-infected patients receiving highly active antiretroviral therapy (HAART) (<LINK REF="REF-Vilchez-2003" TYPE="REFERENCE">Vilchez 2003</LINK>). The possible mechanisms for the increased incidence and altered clinical course of these malignancies in HIV-infected people remain unclear (<LINK REF="REF-Cooley-2003" TYPE="REFERENCE">Cooley 2003</LINK>). The impact of HAART on the epidemiology of HD also remains unclear (<LINK REF="REF-Gates-2002" TYPE="REFERENCE">Gates 2002</LINK>; <LINK REF="REF-Launay-2003" TYPE="REFERENCE">Launay 2003</LINK>). However, a significant improvement in survival has been found in patients with HD-associated HIV on HAART (<LINK REF="REF-Hoffmann-2004" TYPE="REFERENCE">Hoffmann 2004</LINK>; <LINK REF="REF-Hentrich-2005" TYPE="REFERENCE">Hentrich 2005</LINK>).</P>
<P>The outcome of patients with HIV-related HD has improved with better, combined antineoplastic and antiretroviral approaches (<LINK REF="REF-Gerard-2003" TYPE="REFERENCE">Gerard 2003</LINK>; <LINK REF="STD-Spina-2003" TYPE="STUDY">Spina 2003</LINK>); however, there is controversy about the proper treatment. Treatment regimens used to treat HD in immunocompetent patients have been used with some success (<LINK REF="REF-Parekh-2003" TYPE="REFERENCE">Parekh 2003</LINK>). The optimal therapeutic strategy is still controversial, and median overall survival is short, ranging from 12 to 18 months (<LINK REF="REF-Calza-2003" TYPE="REFERENCE">Calza 2003</LINK>); it can be explained in part due to the aggressive character of these lymphomas, but also due to the underlying HIV infection (<LINK REF="REF-Krishnan-2002" TYPE="REFERENCE">Krishnan 2002</LINK>). Several approaches have been used to address this concern: high-dose chemotherapy with stem-cell rescue plus gene therapy (<LINK REF="REF-Krishnan-2002" TYPE="REFERENCE">Krishnan 2002</LINK>); chemotherapy regimens with or without radiotherapy; chemotherapy regimens with or without HAART; chemotherapy regimens with or without granulocyte colony-stimulating factor (G-CSF) (<LINK REF="STD-Levine-2000" TYPE="STUDY">Levine 2000</LINK>; <LINK REF="REF-Gastaldi-2002" TYPE="REFERENCE">Gastaldi 2002</LINK>; <LINK REF="STD-Spina-2002" TYPE="STUDY">Spina 2002</LINK>; <LINK REF="STD-Hartmann-2003" TYPE="STUDY">Hartmann 2003</LINK>;); transplantation of genetically modified HLA-matched peripheral blood progenitor cells (<LINK REF="REF-Kang-2002" TYPE="REFERENCE">Kang 2002</LINK>); and autologous hematopoietic stem-cell transplantation (<LINK REF="STD-Gabarre-2004" TYPE="STUDY">Gabarre 2004</LINK>).</P>
<P>This Cochrane review addressed the following research question: What are the effects of the interventions, on overall survival and disease-free survival, in treatment-naive adults with AIDS-associated Hodgkin's lymphoma?</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-04-22 06:33:10 -0700" MODIFIED_BY="[Empty name]">
<P>To assess the effects of different interventions for treating AIDS-associated HDchemotherapy, bone marrow transplantation (BMT), and gene therapy on overall survival and disease-free survival in treatment-naive adults with AIDS.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-04-22 06:33:20 -0700" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-04-22 06:33:20 -0700" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>We included randomised clinical trials irrespective of their publication status (trials could be unpublished or published as an article, an abstract, or a letter), or language. </P>
<P>Quasi-randomised trials, prospective observational studies, and observational studies with a historical control group were excluded.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with previously untreated biopsy-proven AIDS-related HD were included. Studies including patients who had relapsed, patients with AIDS-related non-Hodgkin's lymphoma, or patients with HIV-related primary central nervous system lymphoma were excluded in this review.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Studies using the following interventions were included:</P>
<UL>
<LI> different chemotherapy protocols </LI>
<LI> combination chemotherapies versus other combination chemotherapies, plus other drug or monoclonal antibodies or radiation therapy; or bone marrow transplantation (whether autologous or allogenic)</LI>
<LI> gene therapy</LI>
<LI> any of these interventions described above, with or without HAART</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-04-22 06:33:20 -0700" MODIFIED_BY="[Empty name]">
<P>
<B>
<I>1) Primary outcome measures</I>
</B>:<BR/>1.1. overall survival (the amount of time a participant lives, measured from the beginning of the intervention until the time of death, or the completion of the trial);<BR/>1.2. disease-free survival (the amount of time in months a participant survives without cancer occurring or recurring).<BR/>
<B>
<I>2) Secondary outcome measures:<BR/>
</I>
</B>2.1. quality of life;<BR/>2.2. tumour response rate (the proportion of trial participants whose tumour was reduced in size by a specific amount);<BR/>2.3. adverse events; defined as any untoward medical occurrence not necessarily having a causal relationship with the treatment, but having resulted in the discontinuation of treatment (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>Relevant trials were identified from The Cochrane HIV/AIDS Group Trials Register. </P>
<P>We searched the Cochrane HIV/AIDS Group Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL) on <I>The Cochrane Library</I>, Issue 3, 2006, MEDLINE (1980 to September 2006), EMBASE (1980 to September 2006), AIDSearch (1980 to December 2006), and LILACS<I> </I>(1982 to September 2006). Full details of the Cochrane HIV/AIDS Group methods and the journals handsearched are published in <I>The Cochrane Library</I> in the section on Collaborative Review Groups.</P>
<P>We searched the databases using the search terms "Lymphoma," "Hodgkin' s disease," "AIDS," and "HIV infection," in combination with the search strategy developed by The Cochrane Collaboration (<LINK REF="REF-Alderson-2003" TYPE="REFERENCE">Alderson 2003</LINK>).</P>
<P>We searched the ClinicalTrials.gov website (http://clinicaltrials.gov).</P>
<P>We searched in The International AIDS Society website (http://www.iasociety.org): <BR/> IAS 2001 - 1st IAS Conference on HIV Pathogenesis and Treatment (Buenos Aires, 2001)<BR/> AIDS 2002 - XIV International AIDS Conference (Barcelona, 2002)<BR/> IAS 2003 - 2nd IAS Conference on HIV Pathogenesis and Treatment (Paris, 2003)<BR/> AIDS 2004 - XV International AIDS Conference (Bangkok, 2004)<BR/> IAS 2005 - 3rd Conference on HIV Pathogenesis and Treatment (Rio de Janeiro, 2005)<BR/> AIDS 2006 - XVI International AIDS Conference (Toronto, Canada)</P>
<P>We searched in http://www.centerwatch.com<BR/>We searched in the American Society of Hematology Conference (Until December 2005). <BR/>We searched in the European Hematology Association Conferences (2005, and 2006). <BR/>We searched in ISI Web of Knowledge (1993 to September 2006). <BR/>We also checked the reference lists of all review identified by the above methods.<BR/>See additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> for search strategies.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>
<B>Study Selection</B>
</P>
<P>The three authors assessed each reference identified by the searches to see if they met the inclusion criteria. We were unable to identify any randomised controlled trials eligible for inclusion in this review. Therefore, we could not perform the data analyses that we had planned. If, in future, trials are identified and included in the review, we will adhere to the protocol described below (in future tense). </P>
<P>Each author will assess the quality of the trials independently. We will base our assessment of methodological quality on the proposals described by Jüni (<LINK REF="REF-J_x00fc_ni-2001" TYPE="REFERENCE">Jüni 2001</LINK>). We will examine the adequacy of the method used to generate the allocation sequence; the concealment of allocation; the level of blinding (clinician, participant, or outcome assessor). We will further examine the percentages of dropouts overall in each study and per randomisation arm and we will evaluate whether intention-to-treat analysis has been performed or could be performed for the published information. For each trial, the authors will classify the risk of bias as high, moderate, or low. A trial will be considered to be at low risk of bias if allocation concealment was "done" and blinding of participants, providers, and outcome assessors was coded "yes."</P>
<P>We will use the following definitions in the assessment of the methodological quality.</P>
<P>
<B>Generation of the allocation sequence</B>
<BR/>
</P>
<UL>
<LI> Adequate, if the allocation sequence was generated by a computer or random number table. Drawing of lots, tossing of a coin, shuffling of cards, or throwing dice will be considered as adequate if a person who was not otherwise involved in the recruitment of participants performed the procedure.</LI>
<LI> Unclear, if the trial was described as randomised, but the method used for the allocation sequence generation was not described.</LI>
<LI> Inadequate, if a system involving dates, names, or admittance numbers was used for the allocation of patients. These studies are known as quasi-randomised and will be excluded from the present review.</LI>
</UL>
<P>
<BR/>
<B>Allocation concealment</B>
<BR/>
</P>
<UL>
<LI> Adequate, if the allocation of patients involved a central independent unit, on-site locked computer, identically appearing numbered drug bottles or containers prepared by an independent pharmacist or investigator, or sealed envelopes.</LI>
<LI> Unclear, if the trial was described as randomised, but the method used to conceal the allocation was not described.</LI>
<LI> Inadequate, if the allocation sequence was known to the investigators who assigned participants or if the study was quasi-randomised.</LI>
</UL>
<P>
<BR/>
<B>Blinding (or masking)</B>
<BR/>
</P>
<UL>
<LI> Adequate, if the trial was described as double blind and the method of blinding involved identical placebo or active drugs.</LI>
<LI> Unclear, if the trial was described as double blind, but the method of blinding was not described.</LI>
<LI> Not performed, if the trial was not double blind.</LI>
</UL>
<P>
<BR/>
<B>Follow-up</B>
<BR/>
</P>
<UL>
<LI> Adequate, if the numbers and reasons for dropouts and withdrawals in all intervention groups were described or if it was specified that there were no dropouts or withdrawals.</LI>
<LI> Unclear, if the report gave the impression that there had been no dropouts or withdrawals, but this was not specifically stated.</LI>
<LI> Inadequate, if the number or reasons for dropouts and withdrawals were not described.</LI>
</UL>
<P>
<BR/>
<B>Data Extraction<BR/>
</B>Arturo Marti-Carvajal (AMC) will draw up a standard data-extraction form, and Andrés Cardona-Zorrilla (ACZ), and Myriam Lucía Rodríguez (MLR) will validate it. Then, we will independently extract data and will systematically contact the authors of trials to provide missing data where possible. AMC will enter the data into the computer and ACZ, and MLR will check the data. We will assess randomisation by comparing the baseline characteristics of each group.</P>
<P>
<B>Data Analysis<BR/>
</B>We will use the statistical package (RevMan 4.2.8) provided by The Cochrane Collaboration. </P>
<P>To estimate overall survival and disease-free survival, hazard ratios (HR) will be calculated. </P>
<P>For binary outcome measures, the authors plan to extract the relative risk (RR) for each outcome. <BR/>For continuous outcomes, we plan to record either mean change from baseline for each group or mean post-treatment or intervention values and their standard deviation or standard error for each group. They also plan to calculate a pooled estimate of treatment effect by calculating the weighted mean difference. If statistics are missing (such as standard deviations), we will try to extract them from other relevant information in the paper, such as P values and confidence intervals. If not possible, the first author of the paper will be contacted. We will examine data for skewness using the means and standard deviations as described in the Cochrane Handbook of Systematic Reviews for Interventions (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). If data are skewed, we will present log-transformed data.</P>
<P>In order to allow an intention-to-treat analysis, the authors will seek data on the number of participants by allocated treatment group, irrespective of compliance and whether or not the participant was later thought to be ineligible or otherwise excluded from treatment or follow up.</P>
<P>We will quantify the impact of statistical heterogeneity using I<SUP>2</SUP>, which describes the percentage of total variation across studies that is due to heterogeneity rather than sampling error (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). If the identified studies are comparable enough, we will summarise their findings using a random-effects model. In case of significant heterogeneity we will devote further research to identifying possible causes of heterogeneity by exploring the impact of participants' characteristics.</P>
<P>We anticipate clinical heterogeneity in the estimation of cure for the following participants' characteristics: gender, use of highly active antiretroviral therapy, histology of the lymphoma, stage of the lymphoma, stage of immunodeficiency (CDC stage and CD4 count), risk level, and dose intensive regimes. These different variables would justify subgroup analyses. </P>
<P>If sufficient studies are identified, the authors plan to conduct a sensitivity analysis comparing the results using all studies and using only those of high methodological quality. They will also attempt to assess whether the review is subject to publication bias by using a funnel plot to graphically illustrate variability between studies. If asymmetry is detected, causes other than publication bias will be explored.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Seven hundred and nine references were identified through the initial bibliographical searches. We manually checked the titles and abstracts, but none of the papers were eligible for further evaluation.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>No studies were included.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>The searches did not identify any randomised controlled trials eligible for inclusion in this systematic review, nor were we able to identify any ongoing trials.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-04-22 06:33:46 -0700" MODIFIED_BY="[Empty name]">
<P>We have been unable to identify any clinical trials addressing the efficacy and safety of different interventions for treating AIDS-associated HDchemotherapy, bone marrow transplantation (BMT), or gene therapy on overall survival and disease-free survival in treatment-naive adults with AIDS, the most common non-AIDS-defining malignancy in HIV-infected patients (<LINK REF="REF-Grulich-1999" TYPE="REFERENCE">Grulich 1999</LINK>; <LINK REF="REF-ICHC-2000" TYPE="REFERENCE">ICHC 2000</LINK>; <LINK REF="REF-Besson-2003" TYPE="REFERENCE">Besson 2003</LINK>; <LINK REF="REF-Glaser-2003" TYPE="REFERENCE">Glaser 2003</LINK>; <LINK REF="REF-Herida-2003" TYPE="REFERENCE">Herida 2003</LINK>; <LINK REF="STD-Hartmann-2004" TYPE="STUDY">Hartmann 2004</LINK>; <LINK REF="REF-Hoffmann-2004" TYPE="REFERENCE">Hoffmann 2004</LINK>; <LINK REF="REF-Lim-2005" TYPE="REFERENCE">Lim 2005</LINK>; <LINK REF="REF-Mosthaf-2006" TYPE="REFERENCE">Mosthaf 2006</LINK>). HD inside the HIV setting has an aggressive tumour behaviour (higher frequency of unfavourably histological subtypes, advanced stages at presentation, and poor therapeutic outcome) compared with HD outside the HIV setting (<LINK REF="REF-Calza-2003" TYPE="REFERENCE">Calza 2003</LINK>; <LINK REF="STD-Hartmann-2004" TYPE="STUDY">Hartmann 2004</LINK>; <LINK REF="REF-Thompson-2004" TYPE="REFERENCE">Thompson 2004</LINK>).</P>
<P>There have been at least two decades of innovation in the management of AIDS to improve the quality of treatment management for AIDS patients, but no RCTs investigating the efficacy and safety of interventions for treating AIDS-associated HD on overall survival and disease-free survival in treatment-naive adults with AIDS have yet been conducted. This lack of trials shows a gap between clinical medicine and clinical investigation. Filling this gap may not be simple.</P>
<P>It is widely known that clinicians make practical decisions, often on the basis of inadequate information; decisions about treatment should be taken based on the results of randomised trials (<LINK REF="REF-Chalmers-2004" TYPE="REFERENCE">Chalmers 2004</LINK>). Thusat least in the treatment of AIDS-associated HD in naive adults the intervention choices remain pragmatic, based on available data regarding the lack of RCTs and observational studies, and the experience of the medical practitioner to guide decision making.</P>
<P>What could be the origin of this uncertainty in decision making? First, there is the possibility that no randomised clinical trials answering the research question posed by this systematic review have yet been carried out and published. Second, it is possible that some studies have been carried out, but have remained unpublished due to negative results (<LINK REF="REF-Easterbrook-1991" TYPE="REFERENCE">Easterbrook 1991</LINK>; <LINK REF="REF-Gluud-1998" TYPE="REFERENCE">Gluud 1998</LINK>). This causes publication bias, and thus reduces the possibility of developing valid systematic reviews in certain areas. Third, the existence of high-quality data sufficient to make strong recommendations for any particular intervention varies considerably across medical specialties (<LINK REF="REF-Diringer-2003" TYPE="REFERENCE">Diringer 2003</LINK>). This is influenced by a plethora of factors, ranging from the prevalence of the medical condition to the availability of resources for developing research. Continuing clinical uncertainty does not benefit patients and may increase health-service costs (<LINK REF="REF-Alderson-2000" TYPE="REFERENCE">Alderson 2000</LINK>), but on the other hand, admitting that there is clinical uncertainty helps clarify treatment options and encourages further research (<LINK REF="REF-Alderson-2000" TYPE="REFERENCE">Alderson 2000</LINK>; <LINK REF="REF-Diringer-2003" TYPE="REFERENCE">Diringer 2003</LINK>). The paucity of data on interventions for treating AIDS-associated HD on overall survival and disease-free survival in treatment-naive adults with AIDS should stimulate the development of well-planned randomised trials, in an attempt to evaluate the widespread empirical practice in treating Hodgkin's disease in patients with AIDS.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>No randomised controlled trials of interventions for treating AIDS-associated Hodgkin's disease on overall survival and disease-free survival in treatment-naive adults with AIDS were found for inclusion in this review. Therefore, it was not possible to determine the efficacy and safety of those interventions. Thus, we recommend that until evidence becomes available, clinicians continue to treat patients on a case-by-case basis, given the diagnosis and treatments available to them.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>This systematic review has identified the need for well-designed, adequately powered randomised controlled trials to assess the benefits and harms of interventions for treating AIDS-associated Hodgkin's disease on overall survival and disease-free survival in treatment-naive adults with AIDS, as a way of improving the survival and decreasing mortality in that population. The trials regarding this issue should be structured and reported according to the CONSORT statement (www.consort-statement.org) for improving the quality of reporting of efficacy and get better reports of harms in clinical research (<LINK REF="REF-Ioannidis-2004" TYPE="REFERENCE">Ioannidis 2004</LINK>; <LINK REF="REF-Moher-2004" TYPE="REFERENCE">Moher 2004</LINK>).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We thank the Iberoamerican Cochrane Centre, Barcelona, Spain, with special gratitude to Dr. Xavier Bonfill, Mr. Ivan Solà, and Mrs. Marta Roqué. </P>
<P>We thank Ms. Karishma Busgeeth, and Ms. Joy Oliver (South African Cochrane Centre) for helping us with the trials search.</P>
<P>We thank the peer reviewers for improving the quality of this Cochrane review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Dr Arturo Marti-Carvajal took the lead on writing up the review and acts as guarantor.</P>
<P>Dr Andrés Felipe Cardona identified trials, and drafted parts of the review. </P>
<P>Dr Myriam Lucía Rodríguez identified trials, and drafted parts of the review. </P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES/>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Alfonso-1988" NAME="Alfonso 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alfonso PG, Sanudo EF, Carretero JM, Galindo RC, Altozano JG, Gomez LP, Manga GP</AU>
<TI>Hodgkin's disease in HIV-infected patients</TI>
<SO>Biomedicine &amp; Pharmacotherapy</SO>
<YR>1988</YR>
<VL>42</VL>
<PG>321-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Costello-1998" NAME="Costello 1998" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Costello R, Heuberger L, Petit N, Olive D, Gastaut JA</AU>
<TI>Hodgkin's disease in patients infected with the human immunodeficiency virus</TI>
<SO>La Revue de Médecine Interne</SO>
<YR>1998</YR>
<VL>19</VL>
<PG>558-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Errante-1994" NAME="Errante 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Errante D, Tirelli U, Gastaldi R, Milo D, Nosari AM, Rossi G et al</AU>
<TI>Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian Cooperative Group on AIDS and Tumors (GICAT)</TI>
<SO>Cancer</SO>
<YR>1994</YR>
<VL>73</VL>
<PG>437-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Errante-1994-B" NAME="Errante 1994 B" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Errante D, Zagonel V, Vaccher E, Serraino D, Bernardi D, Sorio R et al</AU>
<TI>Hodgkin's disease in patients with HIV infection and in the general population: comparison of clinicopathological features and survival</TI>
<SO>Annals of Oncology</SO>
<YR>1994</YR>
<VL>5 Suppl 2</VL>
<PG>37-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Errante-1999" NAME="Errante 1999" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Errante D, Gabarre J, Ridolfo AL, Rossi G, Nosari AM, Gisselbrecht C et al</AU>
<TI>Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF</TI>
<SO>Annals of Oncology</SO>
<YR>1999</YR>
<VL>10</VL>
<PG>189-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gabarre-2004" NAME="Gabarre 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gabarre J, Marcelin AG, Azar N, Choquet S, Levy V, Levy Y et al</AU>
<TI>High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease</TI>
<SO>Haematologica</SO>
<YR>2004</YR>
<VL>89</VL>
<PG>1100-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartmann-2003" NAME="Hartmann 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann P, Rehwald U, Salzberger B, Franzen C, Sieber M, Wohrmann A et al</AU>
<TI>BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection</TI>
<SO>Annals of Oncology</SO>
<YR>2003</YR>
<VL>14</VL>
<PG>1562-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hartmann-2004" NAME="Hartmann 2004" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann P, Rehwald U, Salzberger B, Franzen C, Diehl V</AU>
<TI>Current treatment strategies for patients with Hodgkin's lymphoma and HIV infection</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2004</YR>
<VL>4</VL>
<PG>401-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hern_x00e1_ndez-1999" NAME="Hernández 1999" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hernández D</AU>
<TI>Hodgkinïs disease (HD) in patients with and without human immunodeficiency virus (HIV) infection: mopp/abv hybrid chemotherapy treatment</TI>
<TO>Enfermedad de hodgkin en pacientes con y sin la infección por el virus de inmunodeficiencia humana (VIH) tratamiento con el esquema híbrido mopp/abv</TO>
<SO>Archivos del Hospital Vargas</SO>
<YR>1999</YR>
<VL>41</VL>
<PG>199-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hern_x00e1_ndez-2001" NAME="Hernández 2001" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hernández D</AU>
<TI>Hodgkin's disease in patients with and without human immunodeficiency virus (HIV) infection: MOPP/ABV hybrid chemotherapy treatment</TI>
<TO>Enfermedad de hodgkin en pacientes con y sin la infección por el virus de inmunodeficiencia humana (VIH): tratamiento con el esquema híbrido MOPP/ABV</TO>
<SO>Clínica Médica. Hospital de Clínicas Caracas</SO>
<YR>2001</YR>
<VL>6</VL>
<PG>89-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jarrett-1992" NAME="Jarrett 1992" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jarrett RF</AU>
<TI>Hodgkin's disease</TI>
<SO>Baillière's Clinical Haematology</SO>
<YR>1992</YR>
<VL>5</VL>
<PG>57-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levine-2000" NAME="Levine 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN et al</AU>
<TI>Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149)</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2000</YR>
<VL>24</VL>
<PG>444-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levy-1995" NAME="Levy 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levy R, Colonna P, Tourani JM, Gastaut JA, Brice P, Raphael M et al</AU>
<TI>Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors</TI>
<SO>Leukemia &amp; lymphoma</SO>
<YR>1995</YR>
<VL>16</VL>
<PG>451-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monfardini-1991" NAME="Monfardini 1991" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monfardini S, Tirelli U, Vaccher E, Foa R, Gavosto F</AU>
<TI>Hodgkin's disease in 63 intravenous drug users infected with human immunodeficiency virus. Gruppo Italiano Cooperativo AIDS &amp; Tumori (GICAT)</TI>
<SO>Annals of Oncology</SO>
<YR>1991</YR>
<VL>2 Suppl 2</VL>
<PG>201-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nasti-2001" NAME="Nasti 2001" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Nasti G, Angioni S, Nigra E, Ammassari A, Izzi I, Schiantarelli C et al</AU>
<TI>Feasibility of the integration of Stanford V chemotherapy (CT) regimen with highly active antiretroviral therapy (HAART) and G-CSF in patients (PTS) with Hodgkin's disease and HIV infection (HD-HIV)</TI>
<SO>The 1st. IAS Conference on HIV Pathogenesis and Treatment (http://www.iasociety.org/)</SO>
<YR>2001</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Okechukwu-1991" NAME="Okechukwu 1991" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Okechukwu CN, Ross J</AU>
<TI>Hodgkin's lymphoma in a pregnant patient with acquired immunodeficiency syndrome</TI>
<SO>Clinical Oncology (Royal College of Radiologists (Great Britain))</SO>
<YR>1998</YR>
<VL>10</VL>
<PG>410-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Orem-2005" NAME="Orem 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Orem J, Fu P, Ness A, Mwanda WO, Remick SC</AU>
<TI>Oral combination chemotherapy in the treatment of AIDS-associated Hodgkin's disease</TI>
<SO>East African Medical Journal</SO>
<YR>2005</YR>
<VL>82(9 Suppl)</VL>
<PG>S144-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubio-1994" NAME="Rubio 1994" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubio R</AU>
<TI>Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative Study Group of Malignancies Associated with HIV Infection of Madrid</TI>
<SO>Cancer</SO>
<YR>1994</YR>
<VL>73</VL>
<PG>2400-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spina-2000" NAME="Spina 2000" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spina M, Gabarre J, Fasan M, Vaccher E, Tirelli U</AU>
<TI>Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection [Correspondence]</TI>
<SO>AIDS</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>1457-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spina-2002" NAME="Spina 2002" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C, Nigra E et al</AU>
<TI>Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<PG>1984-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spina-2003" NAME="Spina 2003" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spina M, Berretta M, Tirelli U</AU>
<TI>Hodgkin's disease in HIV</TI>
<SO>Hematology/oncology Clinics of North America</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>843-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tirelli-1992" NAME="Tirelli 1992" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tirelli U, Errante D, Vaccher E, Repetto L, Rizzardini G, Spina M et al</AU>
<TI>Hodgkin's disease in 92 patients with HIV infection: the Italian experience. GICAT (Italian Cooperative Group on AIDS &amp; Tumors)</TI>
<SO>Annals of Oncology</SO>
<YR>1992</YR>
<VL>3 Suppl 4</VL>
<PG>69-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tirelli-1995" NAME="Tirelli 1995" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tirelli U, Errante D, Dolcetti R, Gloghini A, Serraino D, Vaccher E et al</AU>
<TI>Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors</TI>
<SO>Journal of Clinical Oncology</SO>
<YR>1995</YR>
<VL>13</VL>
<PG>1758-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tirelli-2005" NAME="Tirelli 2005" YEAR="">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tirelli U, Vaccher E, Rossi G, Schiantarelli C, Fasan M, Spina M</AU>
<TI>Hodgkin&#8217;s Disease and HIV Infection (HD-HIV) in Pre- and Post-HAART Era: The GICAT (Italian Cooperative Group on AIDS and Tumors) Experience in 139 Patients</TI>
<SO>Blood (ASH Annual Meeting Abstracts) 106: Abstract 1437</SO>
<YR>2005</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Alderson-2000" NAME="Alderson 2000" TYPE="JOURNAL_ARTICLE">
<AU>Alderson P, Roberts I</AU>
<TI>Should journals publish systematic reviews that find no evidence to guide practice? Examples from injury research</TI>
<SO>British Medical Journal</SO>
<YR>2000</YR>
<VL>320</VL>
<PG>376-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Alderson-2003" NAME="Alderson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Alderson P, Green S, Higgins JPT, editors. Cochrane Reviewers&#8217; Handbook 4.2.2 [updated November 2004]. In: The Cochrane Library, Issue 1, 2005. Chichester, UK: John Wiley &amp; Sons, Ltd</AU>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berretta-2003" NAME="Berretta 2003" TYPE="JOURNAL_ARTICLE">
<AU>Berretta M, Cinelli R, Martellotta F, Spina M, Vaccher E, Tirelli U</AU>
<TI>Therapeutic approaches to AIDS-related malignancies</TI>
<SO>Oncogene</SO>
<YR>2003</YR>
<VL>22</VL>
<PG>6646-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Besson-2003" NAME="Besson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Besson C, Raphael M</AU>
<TI>Lymphoma genesis in the context of HIV infection</TI>
<TO>Lymphomagenèse au cours de l'infection par le VIH</TO>
<SO>Annales de Médecine Interne (Paris)</SO>
<YR>2003</YR>
<VL>154</VL>
<PG>523-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Biggar-2006" NAME="Biggar 2006" TYPE="JOURNAL_ARTICLE">
<AU>Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA</AU>
<TI>Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS</TI>
<SO>Blood</SO>
<YR>2006</YR>
<VL>108</VL>
<PG>3786-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calza-2003" NAME="Calza 2003" TYPE="JOURNAL_ARTICLE">
<AU>Calza L, Manfredi R, Colangeli V, Dentale N, Chiodo F</AU>
<TI>Hodgkin's disease in the setting of human immunodeficiency virus infection</TI>
<SO>Scandinavian journal of infectious diseases</SO>
<YR>2003</YR>
<VL>35</VL>
<PG>136-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chalmers-2004" NAME="Chalmers 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chalmers I</AU>
<TI>Well informed uncertainties about the effects of treatments. How clinicians and patients respond?</TI>
<SO>British Medical Journal</SO>
<YR>2004</YR>
<VL>328</VL>
<PG>475-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cooley-2003" NAME="Cooley 2003" TYPE="JOURNAL_ARTICLE">
<AU>Cooley TP</AU>
<TI>Non-AIDS-defining cancer in HIV-infected people</TI>
<SO>Hematology/oncology clinics of North America</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>889-99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Diringer-2003" NAME="Diringer 2003" TYPE="JOURNAL_ARTICLE">
<AU>Diringer MN</AU>
<TI>Evidence-based medicine: what do you do when there's no evidence?</TI>
<SO>Critical Care Medicine</SO>
<YR>2003</YR>
<VL>31</VL>
<PG>659-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dolcetti-2001" NAME="Dolcetti 2001" TYPE="JOURNAL_ARTICLE">
<AU>Dolcetti R, Boiocchi M, Gloghini A, Carbone A</AU>
<TI>Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease</TI>
<SO>European journal of cancer</SO>
<YR>2001</YR>
<VL>37</VL>
<PG>1276-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Doweiko-2004" NAME="Doweiko 2004" TYPE="JOURNAL_ARTICLE">
<AU>Doweiko J, Dezube BJ, Pantanowitz L</AU>
<TI>Unusual sites of Hodgkin's lymphoma: CASE 1. HIV-associated Hodgkin's lymphoma of the stomach</TI>
<SO>Journal Clinical Oncology</SO>
<YR>2004</YR>
<VL>22</VL>
<PG>4227-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Easterbrook-1991" NAME="Easterbrook 1991" TYPE="JOURNAL_ARTICLE">
<AU>Easterbrook PJ, Berlin J, Gopalan R, Matthews DR</AU>
<TI>Publication bias in clinical research</TI>
<SO>Lancet</SO>
<YR>1991</YR>
<VL>337</VL>
<PG>867-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellis-2005" NAME="Ellis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ellis DW, Eaton M, Fox RM, Juneja S, Leong AS, Miliauskas J et al</AU>
<TI>Diagnostic pathology of lymphoproliferative disorders</TI>
<SO>Pathology</SO>
<YR>2005</YR>
<VL>37</VL>
<PG>434-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gabarre-2004" NAME="Gabarre 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gabarre J, Marcelin AG, Azar N, Choquet S, Levy V, Levy Y et al</AU>
<TI>High-dose therapy plus autologous hematopoietic stem cell transplantation for human immunodeficiency virus (HIV)-related lymphoma: results and impact on HIV disease</TI>
<SO>Haematologica</SO>
<YR>2004</YR>
<VL>89</VL>
<PG>1100-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gastaldi-2002" NAME="Gastaldi 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gastaldi R, Martino P, Gentile G, Picardi V, De Propris MS, Pirillo MF et al</AU>
<TI>Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony- stimulating factor</TI>
<SO>Annals of oncology</SO>
<YR>2002</YR>
<VL>13</VL>
<PG>1158-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gates-2002" NAME="Gates 2002" TYPE="JOURNAL_ARTICLE">
<AU>Gates AE, Kaplan LD</AU>
<TI>AIDS malignancies in the era of highly active antiretroviral therapy</TI>
<SO>Oncology (Williston Park)</SO>
<YR>2002</YR>
<VL>16</VL>
<PG>657-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gerard-2003" NAME="Gerard 2003" TYPE="JOURNAL_ARTICLE">
<AU>Gerard L, Galicier L, Boulanger E, Quint L, Lebrette MG, Mortier E et al</AU>
<TI>Improved survival in HIV-related Hodgkin's lymphoma since the introduction of highly active antiretroviral therapy</TI>
<SO>AIDS</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>81-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glaser-2003" NAME="Glaser 2003" TYPE="JOURNAL_ARTICLE">
<AU>Glaser SL, Clarke CA, Gulley ML, Craig FE, DiGiuseppe JA, Dorfman RF et al</AU>
<TI>Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998</TI>
<SO>Cancer</SO>
<YR>2003</YR>
<VL>98</VL>
<PG>300-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-1998" NAME="Gluud 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gluud C</AU>
<TI>"Negative trials" are positive! "Negative trials" are positive! "Negative trials" are positive! "Negative trials" are positive!</TI>
<SO>Journal of Hepatology</SO>
<YR>1998</YR>
<VL>28</VL>
<PG>731-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grulich-1999" NAME="Grulich 1999" TYPE="JOURNAL_ARTICLE">
<AU>Grulich AE, Wan X, Law MG, Coates M, Kaldor JM</AU>
<TI>Risk of cancer in people with AIDS</TI>
<SO>AIDS</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>839-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartmann-2003" NAME="Hartmann 2003" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann P, Rehwald U, Salzberger B, Franzen C, Sieber M, Wohrmann A et al</AU>
<TI>BEACOPP therapeutic regimen for patients with Hodgkin's disease and HIV infection</TI>
<SO>Annals of Oncology</SO>
<YR>2003</YR>
<VL>14</VL>
<PG>1562-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hartmann-2004" NAME="Hartmann 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hartmann P, Rehwald U, Salzberger B, Franzen C, Diehl V</AU>
<TI>Current treatment strategies for patients with Hodgkin's lymphoma and HIV infection</TI>
<SO>Expert Review of Anticancer Therapy</SO>
<YR>2004</YR>
<VL>4</VL>
<PG>401-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hentrich-2005" NAME="Hentrich 2005" TYPE="CONFERENCE_PROC">
<AU>Hentrich M, Maretta L, Bogner JR, Schürmann D, Jäger H, Reichelt D et al</AU>
<TI>Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease</TI>
<SO>Haematologica</SO>
<YR>2005 (Abst 0361)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Herida-2003" NAME="Herida 2003" TYPE="JOURNAL_ARTICLE">
<AU>Herida M, Mary-Krause M, Kaphan R, Cadranel J, Poizot-Martin I, Rabaud C et al</AU>
<TI>Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients</TI>
<SO>Journal Clinical Oncology</SO>
<YR>2003</YR>
<VL>21</VL>
<PG>3447-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>British Medical Journal</SO>
<YR>2003;327:557-60</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>In: The Cochrane Library, Issue 3, 2005. Chichester, UK: John Wiley &amp; Sons, Ltd</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hilman-2005" NAME="Hilman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Hilman S, Brammer C</AU>
<TI>Human immunodeficiency virus-associated Hodgkin's disease of the anal canal</TI>
<SO>Clinical oncology (Royal College of Radiologists (Great Britain))</SO>
<YR>2005</YR>
<VL>17</VL>
<PG>69</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hoffmann-2004" NAME="Hoffmann 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hoffmann C, Chow KU, Wolf E, Faetkenheuer G, Stellbrink HJ, van Lunzen J et al</AU>
<TI>Strong impact of highly active antiretroviral therapy on survival in patients with human immunodeficiency virus-associated Hodgkin's disease</TI>
<SO>British Journal of Haematology</SO>
<YR>2004</YR>
<VL>125</VL>
<PG>455-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" NAME="ICH-GCP 1997" TYPE="OTHER">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<TI>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice</TI>
<SO>www.ich.org/cache/compo/276-254-1.html</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICHC-2000" NAME="ICHC 2000" TYPE="JOURNAL_ARTICLE">
<AU>International Collaboration on HIV and Cancer</AU>
<TI>Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus infected adults</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>2000</YR>
<VL>92</VL>
<PG>1823-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ioannidis-2004" NAME="Ioannidis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Ioannidis JP, Evans SJ, Gotzsche PC, O'Neill RT, Altman DG, Schulz K et al</AU>
<TI>Better reporting of harms in randomized trials: an extension of the CONSORT statement</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2004</YR>
<VL>141</VL>
<PG>781-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-J_x00fc_ni-2001" NAME="Jüni 2001" TYPE="JOURNAL_ARTICLE">
<AU>Jüni P, Altman DG, Egger M</AU>
<TI>Systematic reviews in health care: Assessing the quality of controlled clinical trials</TI>
<SO>British Medical Journal</SO>
<YR>2001</YR>
<VL>323</VL>
<NO>7303</NO>
<PG>42-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kang-2002" NAME="Kang 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kang EM, de Witte M, Malech H, Morgan RA, Phang S, Carter C et al</AU>
<TI>Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>99</VL>
<PG>698-701</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krishnan-2002" NAME="Krishnan 2002" TYPE="JOURNAL_ARTICLE">
<AU>Krishnan A, Zaia J, Molina A</AU>
<TI>Stem cell transplantation and gene therapy for HIV-related lymphomas</TI>
<SO>Journal of hematotherapy &amp; stem cell research</SO>
<YR>2002</YR>
<VL>11</VL>
<PG>765-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Launay-2003" NAME="Launay 2003" TYPE="JOURNAL_ARTICLE">
<AU>Launay O, Guillevin L</AU>
<TI>Epidemiology of HIV-associated malignancies</TI>
<TO>Épidémiologie des tumeurs malignes associées à l&#8217;infection par le VIH</TO>
<SO>Bulletin du cancer</SO>
<YR>2003</YR>
<VL>90</VL>
<PG>387-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levine-2000" NAME="Levine 2000" TYPE="JOURNAL_ARTICLE">
<AU>Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN et al</AU>
<TI>Chemotherapy consisting of doxorubicin, bleomycin, vinblastine, and dacarbazine with granulocyte-colony-stimulating factor in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS clinical trials group study (ACTG 149)</TI>
<SO>Journal of Acquired Immune Deficiency Syndromes</SO>
<YR>2000</YR>
<VL>24</VL>
<PG>444-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lim-2005" NAME="Lim 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lim ST, Levine AM</AU>
<TI>Non-AIDS-defining cancers and HIV infection</TI>
<SO>Current HIV/AIDS reports</SO>
<YR>2005</YR>
<VL>2</VL>
<PG>146-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lu-2005" NAME="Lu 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lu P</AU>
<TI>Staging and classification of lymphoma</TI>
<SO>Seminars in Nuclear Medicine</SO>
<YR>2005</YR>
<VL>35</VL>
<PG>160-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lyter-1995" NAME="Lyter 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lyter DW, Bryant J, Thackeray R, Rinaldo CR, Kingsley LA</AU>
<TI>Incidence of human immunodeficiency virus-related and nonrelated malignancies in a large cohort of homosexual men</TI>
<SO>Journal Clinical Oncology</SO>
<YR>1995</YR>
<VL>13</VL>
<PG>2540-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Massarweh-2003" NAME="Massarweh 2003" TYPE="JOURNAL_ARTICLE">
<AU>Massarweh S, Udden MM, Shahab I, Kroll M, Sears DA, Lynch GR et al</AU>
<TI>HIV-related Hodgkin's disease with central nervous system involvement and association with Epstein-Barr virus</TI>
<SO>American Journal of Hematology</SO>
<YR>2003</YR>
<VL>72</VL>
<PG>216-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2004" NAME="Moher 2004" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Altman DG, Schulz KF, Elbourne DR</AU>
<TI>Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond</TI>
<SO>Canadian Medical Association Journal</SO>
<YR>2004</YR>
<VL>171</VL>
<PG>349-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mosthaf-2006" NAME="Mosthaf 2006" TYPE="JOURNAL_ARTICLE">
<AU>Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H</AU>
<TI>High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review</TI>
<TO>Hohe inzidenz nicht AIDS-definierender neoplasien bei HIV-infizierten patienten in Deutschland. Ein 3-jähriger bundesweiter Überblick</TO>
<SO>Deutsche medizinische Wochenschrift</SO>
<YR>2006</YR>
<VL>131</VL>
<PG>1849-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Parekh-2003" NAME="Parekh 2003" TYPE="JOURNAL_ARTICLE">
<AU>Parekh S, Ratech H, Sparano JA</AU>
<TI>Human immunodeficiency virus-associated lymphoma</TI>
<SO>Clinical advances in hematology &amp; oncology</SO>
<YR>2003</YR>
<VL>1</VL>
<PG>295-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poluri-2002" NAME="Poluri 2002" TYPE="JOURNAL_ARTICLE">
<AU>Poluri A, Shah KG, Carew JF, Shaha AR, Har-El G, Lucente FE, Singh B.</AU>
<TI>Hodgkin's disease of the head and neck in human immunodeficiency virus-infected patients</TI>
<SO>American journal of otolaryngology</SO>
<YR>2002</YR>
<VL>23</VL>
<PG>12-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ponzoni-2002" NAME="Ponzoni 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ponzoni M, Fumagalli L, Rossi G, Freschi M, Re A, Vigano MG et al</AU>
<TI>Isolated bone marrow manifestation of HIV-associated Hodgkin lymphoma</TI>
<SO>Modern pathology</SO>
<YR>2002</YR>
<VL>15</VL>
<PG>1273-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rapezzi-2001" NAME="Rapezzi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rapezzi D, Ugolini D, Ferraris AM, Racchi O, Gaetani GF</AU>
<TI>Histological subtypes of Hodgkin's disease in the setting of HIV infection</TI>
<SO>Annals of hematology</SO>
<YR>2001</YR>
<VL>80</VL>
<PG>340-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Re-2001" NAME="Re 2001" TYPE="JOURNAL_ARTICLE">
<AU>Re A, Casari S, Cattaneo C, Facchetti F, Cadeo G, Carosi G et al</AU>
<TI>Hodgkin disease developing in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma</TI>
<SO>Cancer</SO>
<YR>2001</YR>
<VL>92</VL>
<PG>2739-45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Serraino-2000" NAME="Serraino 2000" TYPE="JOURNAL_ARTICLE">
<AU>Serraino D, Boschini A, Carrieri P, Pradier C, Dorrucci M, Dal Maso L et al</AU>
<TI>Cancer risk among men with, or at risk of, HIV infection in southern Europe</TI>
<SO>AIDS</SO>
<YR>2000</YR>
<VL>14</VL>
<PG>553-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spina-2002" NAME="Spina 2002" TYPE="JOURNAL_ARTICLE">
<AU>Spina M, Gabarre J, Rossi G, Fasan M, Schiantarelli C, Nigra E et al</AU>
<TI>Stanford V regimen and concomitant HAART in 59 patients with Hodgkin disease and HIV infection</TI>
<SO>Blood</SO>
<YR>2002</YR>
<VL>100</VL>
<PG>1984-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Spina-2003" NAME="Spina 2003" TYPE="JOURNAL_ARTICLE">
<AU>Spina M, Berretta M, Tirelli U</AU>
<TI>Hodgkin's disease in HIV</TI>
<SO>Hematology/oncology Clinics of North America</SO>
<YR>2003</YR>
<VL>17</VL>
<PG>843-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thompson-2004" NAME="Thompson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Thompson LD, Fisher SI, Chu WS, Nelson A, Abbondanzo SL</AU>
<TI>HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases</TI>
<SO>American Journal of Clinical Pathology</SO>
<YR>2004</YR>
<VL>121</VL>
<PG>727-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vilchez-2003" NAME="Vilchez 2003" TYPE="JOURNAL_ARTICLE">
<AU>Vilchez RA, Finch CJ, Jorgensen JL, Butel JS</AU>
<TI>The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era</TI>
<SO>Medicine (Baltimore)</SO>
<YR>2003</YR>
<VL>82</VL>
<PG>77-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2005" NAME="Wood 2005" TYPE="JOURNAL_ARTICLE">
<AU>Wood C, Harrington W Jr</AU>
<TI>AIDS and associated malignancies</TI>
<SO>Cell research</SO>
<YR>2005</YR>
<VL>15</VL>
<PG>947-52</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Alfonso-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cases report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Costello-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Errante-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Errante-1994-B">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cases report.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Errante-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gabarre-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT.<BR/>Included patients with relapsed or resistant ARL (nonHodgkin's lymphoma and with Hodgkin's disease).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hartmann-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hartmann-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hern_x00e1_ndez-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hern_x00e1_ndez-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jarrett-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levine-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Levy-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cases report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Monfardini-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cases report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nasti-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Okechukwu-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case report</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Orem-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rubio-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spina-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spina-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spina-2003">
<CHAR_REASON_FOR_EXCLUSION>
<P>Review</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tirelli-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tirelli-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cohort study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tirelli-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial.<BR/>ARL: AIDS-related lymphoma.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Search strategy</TITLE>
<TABLE COLS="4" ROWS="10">
<TR>
<TH>
<P>DATABASE</P>
</TH>
<TH>
<P>STRATEGY</P>
</TH>
<TH>
<P>RESULTS</P>
</TH>
<TH>
<P># iNCLUDED STUDIES</P>
</TH>
</TR>
<TR>
<TD>
<P>MEDLINE</P>
</TD>
<TD>
<P>#8 Search #5 AND #6 AND #7<BR/>#7 Search HODGKINS DISEASE OR HODGKIN'S DISEASE OR HODGKIN DISEASE OR HODGKIN LYMPHOMA OR HODGKIN'S LYMPHOMA OR HODGKINS LYMPHOMA<BR/>#6 Search "HIV Infections"[MeSH] OR "HIV"[MeSH] OR hiv [tw] OR hiv-1*[tw] OR hiv-2*[tw] OR hiv1[tw] OR hiv2[tw] OR hiv infect*[tw] OR human immunodeficiency virus[tw] OR human immunedeficiency virus[tw] OR human immuno-deficiency virus[tw] OR human immune-deficiency virus[tw] OR ((human immun*) AND (deficiency virus[tw])) OR acquired immunodeficiency syndrome[tw] OR acquired immunedeficiency syndrome[tw] OR acquired immuno-deficiency syndrome[tw] OR acquired immune-deficiency syndrome[tw] OR ((acquired immun*) AND (deficiency syndrome[tw])) OR "Lymphoma, AIDS-Related"[MeSH] OR "Sexually Transmitted Diseases, Viral"[MeSH:NoExp]<BR/>#5 Search randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT human [mh])<BR/>
<BR/>
</P>
</TD>
<TD>
<P>190</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>EMBASE (1980-2006)</P>
</TD>
<TD>
<P>1 ('human immunodeficiency virus infection'/exp) OR ('human immunodeficiency virus'/exp) OR (hiv:ti OR hiv:ab) OR ('hiv-1':ti OR 'hiv-1':ab) OR ('hiv-2':ti OR 'hiv-2':ab) OR ('human immunodeficiency virus':ti OR 'human immunodeficiency virus':ab) OR ('human immuno-deficiency virus':ti OR 'human immuno-deficiency virus':ab) OR ('human immunedeficiency virus':ti OR 'human immunedeficiency virus':ab) OR ('human immune-deficiency virus':ti OR 'human immune-deficiency virus':ab) OR ('acquired immune-deficiency syndrome':ti OR 'acquired immune-deficiency syndrome':ab) OR ('acquired immunedeficiency syndrome':ti OR 'acquired immunedeficiency syndrome':ab) OR ('acquired immunodeficiency syndrome':ti OR 'acquired immunodeficiency syndrome':ab) OR ('acquired immuno-deficiency syndrome':ti OR 'acquired immuno-deficiency syndrome':ab) <BR/>#2 (random*:ti OR random*:ab) OR (factorial*:ti OR factorial*:ab) OR (cross?over*:ti OR cross?over:ab OR crossover*:ti OR crossover*:ab) OR (placebo*:ti OR placebo*:ab) OR (((doubl*:ti AND blind*:ti) OR (doubl*:ab AND blind*:ab))) OR (((singl*:ti AND blind*:ti) OR (singl*:ab AND blind*:ab))) OR (assign*:ti OR assign*:ab) OR (volunteer*:ti OR volunteer*:ab) OR ('crossover procedure'/de) OR ('double-blind procedure'/de) OR ('single-blind procedure'/de) OR ('randomized controlled trial'/de) OR (allocat*:ti OR allocat*:ab) <BR/>#4 ('hodgkins disease'/exp OR 'hodgkins disease') OR ('hodgkin's AND disease') or ('hodgkin AND disease') or ('hodgkin AND lymphoma') or ('hodgkin's lymphoma') OR ('hodgkins lymphoma') <BR/>#5 #1 AND #2 AND #4<BR/>
</P>
</TD>
<TD>
<P>14</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>LILACS</P>
</TD>
<TD>
<P>(hodgkin$ AND (hiv OR aids)) AND (((Pt randomized controlled trial OR Pt controlled clinical trial OR Mh randomized controlled trials OR Mh random allocation OR Mh double-blind method OR Mh single-blind method) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Pt clinical trial OR Ex E05.318.760.535$ OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh placebos OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh research design) AND NOT (Ct animal AND NOT (Ct human and Ct animal)) OR (Ct comparative study OR Ex E05.337$ OR Mh follow-up studies OR Mh prospective studies OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct animal AND NOT (Ct human and Ct animal))))</P>
</TD>
<TD>
<P>36</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>CENTRAL (1980-2006)</P>
</TD>
<TD>
<P>#1hiv OR hiv-1* OR hiv-2* OR hiv1 OR hiv2 OR (HIV INFECT*) OR (HUMAN IMMUNODEFICIENCY VIRUS) OR (HUMAN IMMUNEDEFICIENCY VIRUS) OR (HUMAN IMMUNE-DEFICIENCY VIRUS) OR (HUMAN IMMUNO-DEFICIENCY VIRUS) OR (HUMAN IMMUN* DEFICIENCY VIRUS) OR (ACQUIRED IMMUNODEFICIENCY SYNDROME) OR (ACQUIRED IMMUNEDEFICIENCY SYNDROME) OR (ACQUIRED IMMUNO-DEFICIENCY SYNDROME) OR (ACQUIRED IMMUNE-DEFICIENCY SYNDROME) OR (ACQUIRED IMMUN* DEFICIENCY SYNDROME) in All Fields in all products<BR/>#2MeSH descriptor HIV Infections explode all trees in MeSH products<BR/>#3MeSH descriptor HIV explode all trees in MeSH products<BR/>#4(#1 OR #2 OR #3)<BR/>#5((ANIMAL OR ANIMALS) AND (NOT HUMANS)) in All Fields in all products<BR/>#6HODGKINS DISEASE OR HODGKIN'S DISEASE OR HODGKIN DISEASE OR HODGKIN LYMPHOMA OR HODGKIN'S LYMPHOMA OR HODGKINS LYMPHOMA<BR/>#7(#4 AND #6)<BR/>#8(#7 AND NOT #5)<BR/>#9(#8), from 1980 to 2006<BR/>
</P>
</TD>
<TD>
<P>52</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>ClinicalTrials.gov website</P>
</TD>
<TD>
<P>Hodgkin's disease AND AIDS OR HIV</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>International AIDS Society</P>
</TD>
<TD>
<P>Hodgkin's disease</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>ISI Web of Knowledge (1993 to September 2006) <BR/>
</P>
</TD>
<TD>
<P>Hodgkin's disease AND AIDS OR HIV AND Randomised OR Randomized</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>American Society of Hematology (until December 2005)</P>
</TD>
<TD>
<P>Hodgkin's disease AND HIV OR AIDS</P>
</TD>
<TD>
<P>6</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
<TR>
<TD>
<P>AIDSearch (1980 to December 2006)</P>
</TD>
<TD>
<P># 1 PT = Randomized Controlled Trial<BR/># 2 PT = Controlled Clinical Trial<BR/># 3 Randomized Controlled Trial<BR/># 4 Random Allocation<BR/># 5 Doubled Blind Method<BR/># 6 Single Blind Method<BR/># 7 PT = Clinical Trial<BR/># 8 Clinical Trials OR Clinical Trials, Phase 1 OR Clinical Trials, Phase II OR Clinical Trials<BR/># 9 (Singl* OR Doubl* OR Trebl* OR Tripl*) Nears (Blind* OR Mask*)<BR/># 10 Clin* Nears Trial*<BR/># 11 Placebo*<BR/># 12 Placebos<BR/># 13 Random* <BR/># 14 Research Design<BR/># 15 #1 OR #2 #3 OR #4 #5 OR #6 #7 OR #8 #9 OR #10 #11 OR #12 #13 OR #14<BR/># 16 Animals Not (Human AND Animals)<BR/># 17 #15 OR #16<BR/># 18 Hodgkins Disease OR Hodgkin's Disease OR Hodgkin Disease OR Hodgkin Lymphoma<BR/># 19: #17 AND #18 AND PY = 1980-2006<BR/>
<BR/>
</P>
</TD>
<TD>
<P>392</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES"/>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>